We can’t show the full text here under this license.
EClinicalMedicine···
Blood Sugar Effects of GLP-1 Hormone-Based Treatments in Type 2 Diabetes
Updated
Abstract
Tirzepatide 15 mg ranked first in HbA1c reduction among GLP-1 receptor agonist-based treatments.
- Tirzepatide 15 mg showed a significant reduction in HbA1c compared to iDegLira and iGlarLixi, with mean differences of -0.40% and -0.48% respectively.
- The treatment did not increase the risk of hypoglycaemia when compared to iDegLira and iGlarLixi.
- Tirzepatide 15 mg was also the most effective for weight loss, exceeding the effects of high-dose GLP-1 receptor agonists and GLP-1RA plus SGLT-2i combinations.
- Overall, low risk of bias and publication bias were observed across the included studies, although high heterogeneity was prevalent for most outcomes.
Simplified
BACKGROUND: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies-such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations, and high-dose GLP-1RA-have been listed among the most efficacious options for type 2 diabetes management. However, differences in their glucometabolic effects have not been assessed in dedicated head-to-head trials. In the absence of such trials, we aimed to provide a useful comparison among these treatment strategies to guide clinical practice.
METHODS: In this network meta-analysis, we searched PubMed, MEDLINE, and Web of Science (from database inception to June 24, 2023) for randomised controlled studies, published in English, that enrolled individuals with type 2 diabetes treated with tirzepatide, iGlarLixi, iDegLira, GLP-1RA plus SGLT-2i combination, or high-dose GLP-1RA (dulaglutide 3 mg and 4.5 mg, semaglutide 2 mg) compared with placebo or active comparators. Eligible studies reported change from baseline in HbA1c as an outcome, which was the primary outcome of this analysis. Secondary outcomes were changes in fasting and post-prandial glucose, bodyweight, LDL-cholesterol, blood pressure and risk of hypoglycaemia. We assessed risk of bias through the Cochrane Collaboration's tool (RoB2 tool), publication bias through visual inspection of funnel plots and Egger's test, and heterogeneity by comparing the magnitude of the common between-study variance (τ) for each outcome with empirical distributions of heterogeneity variances. This network meta-analysis was registered in PROSPERO (CRD42022329878). 2
FINDINGS: 40 trials were included. Tirzepatide 15 mg ranked first in terms of HbA1c reduction compared to other GLP-1RA-based strategies, even those including insulin (vs. iDegLira MD -0.40%, 95% CI [-0.66; -0.14], low certainty; vs. iGlarLixi MD -0.48%, 95% CI [-0.75; -0.21], low certainty), without increasing the risk of hypoglycaemia (vs. iDegLira OR 0.35, 95% CI [0.16; 0.79], high certainty; vs. iGlarLixi OR 0.31, 95% CI [0.20; 0.48], high certainty). Tirzepatide 15 mg was also the most efficacious on weight lowering, even compared to high-dose GLP-1RA (eg, semaglutide 2 mg MD -6.56 kg, 95% CI [-7.38; -5.73], low certainty) and GLP-1RA plus SGLT-2i combination (MD -4.61 kg, 95% CI [-5.29; -3.93], low certainty). Risk of bias and publication bias were generally low throughout studies, while high levels of heterogeneity were detected for most outcomes.
INTERPRETATION: Aiming to support clinicians in tailoring treatment to patients' needs, we suggest that a hierarchy among treatment strategies be devised considering the best options for type 2 diabetes. Tirzepatide, followed by GLP-1RA plus basal insulin FRC and GLP-1RA plus SGLT-2i combination, was associated with greater benefit on HbA1c than high-dose GLP-1RA.
FUNDING: Fondazione per la Ricerca Biomedica "Saverio e Isabella Cianciola" and Next Generation EU, in the context of the National Recovery and Resilience Plan, Investment PE8-Project Age-It: Ageing Well in an Ageing Society.
Related papers
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 29 papers
systematic review
May '22
Using tirzepatide, a drug that activates two hormone receptors, to manage type 2 diabetes: a combined review and analysis
top 2% journal
cited by 222 papers
systematic review
Apr '23
Benefits and harms of medicines for type 2 diabetes: review and comparison of clinical trials
top 5% journal
cited by 225 papers
systematic review
Jun '23
Factors linked to how well SGLT-2 inhibitors versus GLP-1 receptor agonists reduce major heart problems in type 2 diabetes
top 2% journal
cited by 25 papers
meta-analysis
Jan '24
GLP-1 drugs' effects on blood sugar, weight, and fat levels in type 2 diabetes
top 5% journal
cited by 399 papers
systematic review
May '20
Do GLP-1 and SGLT-2 medications lower heart risks in women with type 2 diabetes? A review and combined analysis
top 10% journal
cited by 11 papers
systematic review
Jan '24
Combined GLP-1 and SGLT-2 treatments and heart problems after a heart attack in people with type 2 diabetes
top 2% journal
cited by 56 papers
observational study
Apr '20
Effects of Diabetes Drugs Alone and Combined on Blood Vessel Lining, Artery Health, and Heart Work in Type 2 Diabetes After One Year
top 5% journal
cited by 161 papers
randomized controlled trial